Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, University Health Network, University of Toronto, 399 Bathurst Street, Toronto, Ontario, 1E-410B, Canada.
Curr Rheumatol Rep. 2021 Apr 28;23(6):35. doi: 10.1007/s11926-021-00999-8.
To review current understanding of the prevalence, clinical features, outcome measures and recent therapeutic trials in axial psoriatic arthritis (axPsA).
The prevalence of axPsA is estimated at 40-50%. However, the definition of axPsA remains unclear, therefore these estimates may be inaccurate. Ax PsA appears to be distinct from ankylosing spondylitis in demographic, clinical, genetic and therapeutic features. Because of the lack of widely accepted definition of axPsA it has been difficult to design therapeutic trials for this domain of PsA. Several studies have demonstrated the uniquness of axPsA. Few recent trials suggest that therapies that work for peripheral arthritis also work for axPsA.
综述目前对轴性银屑病关节炎（axPsA）的患病率、临床特征、疗效评估及近期治疗试验的认识。
axPsA 的患病率估计为 40-50%。然而，axPsA 的定义仍不明确，因此这些估计可能不准确。Ax PsA 在人口统计学、临床、遗传学和治疗特征方面与强直性脊柱炎不同。由于 axPsA 缺乏广泛接受的定义，因此很难为这一领域的 PsA 设计治疗试验。几项研究表明 axPsA 的独特性。最近的一些试验表明，对周围关节炎有效的治疗方法也适用于 axPsA。
